Blog

BMF-650: An Oral GLP-1 Designed to Skip the Titration Grind Posted Phase 1 Data

Biomea Fusion's oral small-molecule GLP-1 hit target dose in one step with mild side effects. Phase 1 results from October 13, and why the design matters.

Everyone in the peptide community knows the drill with GLP-1s: start low, go slow, spend months climbing a titration ladder while your stomach files complaints at every rung. Semaglutide and tirzepatide both need multi-month escalation schedules. So when a company shows up claiming its oral GLP-1 can go from zero to target dose in a single step, that is worth a closer look.

Biomea Fusion did exactly that. On October 13 the company posted Phase 1 results for BMF-650, an oral small-molecule GLP-1 receptor agonist, and the headline is not the weight loss number - it is the tolerability architecture.

What the Research Says

The Phase 1 trial (GLP-131, NCT07223216) was a randomised, double-blind, placebo-controlled study in otherwise healthy adults with overweight or obesity. It ran a single ascending dose portion followed by five multiple ascending dose (MAD) cohorts over four weeks. The full results are in Biomea’s October 13 release.

The numbers:

  • Mean weight reduction across Cohorts 1-4 ranged from 1.5% to 3.2% at Day 29, versus 0.1% for pooled placebo
  • At doses of 200 mg or higher once daily, mean weekly weight reduction was roughly 0.97 kg
  • Across all five active-dose MAD cohorts (n=40), every treatment-emergent adverse event was mild or moderate. No severe or serious events, no dose modifications, no discontinuations
  • Nausea showed up in 17.5% of active-dose participants, vomiting in 7.5%, constipation in 10%, diarrhoea in 5%. All Grade 1 or 2
  • No liver enzyme (ALT/AST) elevations were reported at all

Cohort 5 is where the design claim gets tested. Those participants jumped from 200 mg once daily to the 400 mg target dose after just one week, instead of the slow multi-step ramp. They tolerated it the same as everyone else: nausea and vomiting at 12.5% each, all mild. The company reads that as support for testing a “no titration” regimen in later trials.

Why the Chemistry Matters

BMF-650 is a small molecule, not a peptide - same broad category as orforglipron, Lilly’s oral GLP-1. The design logic is spelled out by Thorsten Kirschberg, the program lead, in the release: they deliberately engineered the molecule for less acute GLP-1 receptor agonism in the gut, aiming to keep weight loss while dialling down the GI side effects that force those long titration schedules.

The pitch is blunt. Titration schedules on existing GLP-1s “can take 5 months or more,” and every month on a sub-tolerable dose is a month people quit. If you can flatten that ramp, persistence with the therapy changes. The pharmacokinetic data back the once-daily story: sustained exposures with a low peak-to-trough ratio, which is what you want if the theory is steady receptor engagement without the spikes that trigger nausea.

There is a comparison worth making here. Lilly’s orforglipron went through the same scepticism at Phase 1 - a small molecule with peptide-like efficacy seemed too good - and then delivered in Phase 3. BMF-650 is nowhere near that point. Its Phase 1 weight loss (3.2% at four weeks in the top tolerability cohorts) is early and modest, and four-week Phase 1 numbers have a habit of looking different at 72 weeks.

The Fine Print

This is a Phase 1. Forty active-dose participants, four weeks, healthy adults, no comparator arm beyond placebo. The company itself notes that BMF-650’s development focus sits behind its menin inhibitor program for diabetes, and it is openly shopping for collaboration partners to take the GLP-1 forward. That is corporate-speak for: this molecule’s next step depends on someone else’s money.

Also worth noting: the 0.97 kg/week figure comes from Cohorts 1-4 pooled at 200 mg-plus, and additional analysis is still ongoing with results promised at a future medical meeting. Peer review has not touched this yet.

So the honest read is: interesting mechanism, genuinely novel tolerability approach, very early data. If the “no titration” thesis holds in Phase 2, it matters commercially for every oral GLP-1 in the pipeline. If it does not, BMF-650 becomes another molecule that tried to out-engineer the GLP-1 nausea problem.

For context on where oral GLP-1s sit overall, our semaglutide overview covers the injectable incumbent, and our tirzepatide page covers the dual-agonist class leader.

If you want to argue about whether small-molecule GLP-1s can ever match peptide pharmacokinetics, the Grey Highway Telegram group is where that debate lives.

Sources

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.